Unknown

Dataset Information

0

Avoidance of On-Target Off-Tumor Activation Using a Co-stimulation-Only Chimeric Antigen Receptor.


ABSTRACT: Chimeric antigen receptors (CARs) combine T cell activation with antibody-mediated tumor antigen specificity, bypassing the need for T cell receptor (TCR) ligation. A limitation of CAR technology is on-target off-tumor toxicity caused by target antigen expression on normal cells. Using GD2 as a model cancer antigen, we hypothesized that this could be minimized by using T cells expressing V?9V?2 TCR, which recognizes transformed cells in a major histocompatibility complex (MHC)-unrestricted manner, in combination with a co-stimulatory CAR that would function independently of the TCR. An anti-GD2 CAR containing a solitary endodomain derived from the NKG2D adaptor DAP10 was expressed in V?9V?2+ T cells. Differential ligation of the CAR and/or TCR using antibody-coated beads showed that pro-inflammatory cytokine response depended on activation of both receptors. Moreover, in killing assays, GD2-expressing neuroblastoma cells that engaged the V?9V?2 TCR were efficiently lysed, whereas cells that expressed GD2 equivalently but did not engage the V?9V?2 TCR were untouched. Differentiation between X-on tumor and X-off tumor offers potential for safer immunotherapy and broader target selection.

SUBMITTER: Fisher J 

PROVIDER: S-EPMC5417796 | biostudies-literature | 2017 May

REPOSITORIES: biostudies-literature

altmetric image

Publications

Avoidance of On-Target Off-Tumor Activation Using a Co-stimulation-Only Chimeric Antigen Receptor.

Fisher Jonathan J   Abramowski Pierre P   Wisidagamage Don Nisansala Dilrukshi ND   Flutter Barry B   Capsomidis Anna A   Cheung Gordon Weng-Kit GW   Gustafsson Kenth K   Anderson John J  

Molecular therapy : the journal of the American Society of Gene Therapy 20170322 5


Chimeric antigen receptors (CARs) combine T cell activation with antibody-mediated tumor antigen specificity, bypassing the need for T cell receptor (TCR) ligation. A limitation of CAR technology is on-target off-tumor toxicity caused by target antigen expression on normal cells. Using GD2 as a model cancer antigen, we hypothesized that this could be minimized by using T cells expressing Vγ9Vδ2 TCR, which recognizes transformed cells in a major histocompatibility complex (MHC)-unrestricted manne  ...[more]

Similar Datasets

| S-EPMC5363190 | biostudies-literature
| S-EPMC6287795 | biostudies-literature
2021-12-10 | GSE186557 | GEO
| S-EPMC10703879 | biostudies-literature
| S-EPMC9127424 | biostudies-literature
| S-EPMC7704745 | biostudies-literature
| S-EPMC5628114 | biostudies-literature
| S-EPMC5794762 | biostudies-literature
| S-EPMC8863855 | biostudies-literature
| S-EPMC9080078 | biostudies-literature